A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

PHASE3CompletedINTERVENTIONAL

Enrollment

833

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

January 31, 2012

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG

Ibandronate

Ibandronate 150mg PO QM (tablet)

DRUG

Denosumab

denosumab 60mg SC Q6M (pre-filled syringe)